Company intelligence / Profile preview
CD Biopharma
Suzhou, Jiangsu Province, Chinacdbiopharma.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
The company’s lead candidate, CD‑001, has received FDA IND clearance and entered Phase I clinical trials. Preclinical studies showed efficacy in mouse tumor models and good tolerance in non-human primates. An armored PD1Ab21-CD19 CAR-T therapy has shown complete remission in the first three patients of an investigator-led trial at a top Beijing hospital with well-managed safety. Initial clinical data from the ongoing trial are expected soon.
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- Bispecific fusion proteins (BsFP)Armored CAR-T cell therapyMonoclonal antibodiesAntibody-cytokine fusion proteins
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on CD Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD Biopharma.